Absolute granulocyte count (AGC) >= 1,500/mm^3, within 4 weeks of randomization
Absolute granulocyte count >= 1.2 x 10^3/mm^3
Granulocyte 1500 cells/mm3
Granulocyte > 1500/ul within four weeks of enrollment
Absolute granulocyte count >= 1000 K/uL
Absolute granulocyte count >= 1,500/mm^3 (1.5 x 10^9/L)
Absolute granulocyte count >= 1,500/mcL, within 16 days of starting therapy
Granulocyte count ? 1000/mm^3
Absolute granulocyte count < 1000; platelets <100,000.
Granulocyte count >= 1000/mm3 ((within 16 days before starting therapy)
Granulocyte count >= 1000/mm^3 (within 16 days before starting therapy)
Granulocyte count <1500/mm3
Absolute granulocyte count < 1000; platelets <100,000.
Granulocyte count >= 1,500/mm^3 (within 16 days of enrollment)
Granulocyte count > 1500/mm^3
Marrow: Hemoglobin ?10.0 gm/dL, absolute granulocyte count (AGC) ?1,000/mm3 platelets ?100,000/mm3, absolute lymphocyte count ?1000/mm3.
Granulocyte count >= 1,500/mm^3
Peripheral absolute granulocyte count of > 1000/mm^3
Granulocyte count >= 1500/mm^3
A. Marrow: Hemoglobin ?10.0 gm/dL, absolute granulocyte count (AGC) ?1,000/mm3, platelets ?75,000/mm3, absolute lymphocyte count ?475/mm3.
Granulocyte count >= 1,500/mm3
Granulocyte count >= 1500/mm^3
Absolute granulocyte count (AGC) >= 1,500
Granulocyte >= 1500/ul
Absolute granulocyte count < 1,500/ul
Absolute granulocyte count < 1,500/ul
Absolute granulocyte count > 1.5 x 10^3/mm3
Absolute granulocyte count >= 1.2 x 10^3/mm^3
Granulocyte count ? 1500/mm^3 ? 2 weeks
Granulocyte >= 1,500/uL
Absolute granulocyte count >= 1.0 x 10^3/mm^3
Peripheral granulocyte count of > 1,500/mm^3
Absolute granulocyte count (AGC) >= 1,500 cells/mm^3
Granulocyte count >= 1,500/mm^3
Absolute granulocyte count >= 1,500/mm^3
Granulocyte > 1500/ul
Granulocyte count of at least 1,500/uL
Granulocyte >= 1500/ul
Granulocyte count >= 1,000/uL for lapatinib and > 1,500/uL for capecitabine
Absolute granulocyte count > 1,500/mcL
Absolute granulocyte count (AGC) >= 1,500/mm³
Granulocyte count >= 1000/mm^3 (within 16 days before starting therapy)
Peripheral granulocyte count of >= 1,500/mL
Granulocyte count >= 1,500/mm^3
Peripheral granulocyte count of >= 1500/mm³
Marrow: Hemoglobin ?10.0 gm/dL, absolute granulocyte count (AGC) ?1,000/mm3, platelets ?75,000/mm3, absolute lymphocyte count ?475/mm3.
Granulocyte count >= 1000/mm^3 (within 16 days before starting therapy)
Granulocyte count >= 1500/mm^3
Granulocyte count >= 1500/mm^3
Marrow: Hemoglobin ?10.0 dm/dL, absolute granulocyte count (AGC)?1,000/mm^3, platelets ?100,000/mm^3, absolute lymphocyte count ?1000/mm^3.
Granulocyte count >= 1000/mm^3
Absolute peripheral granulocyte count of >= 1,000/mm^3
Normal organ and marrow function as defined below: Absolute granulocyte count ? 1,500/mm3 Absolute lymphocyte count ? 500/mm3 Platelets ? 100,000/mm3 Total bilirubin ?2 mg/dL AST(SGOT)/ALT(SGPT) <2x institutional upper limit of normal Creatinine <1.5 mg/dL
Absolute granulocyte count >= 1,500/mm^3
Absolute granulocyte count >= 500/mm^3
An absolute granulocyte count > 1500/µL
Absolute granulocyte count (AGC) >= 2000 cells/mm^3
Absolute granulocyte count (ANC) >= 1.2 x 10^3/mm^3
Granulocyte count >= 1,500/mm^3 within 16 days of starting therapy
Granulocyte count >= 1,000/uL
Absolute granulocyte count >= 1.5 x 10^9/L
Granulocyte count > 1000/mm^3
Total granulocyte count of > 1500
Total granulocyte count of > 1.5 x 10^9/L
Patients should have adequate bone marrow function defined by an absolute peripheral granulocyte count of > 1,500 /mm3 and platelet count >100,000/mm3 along with an absence of a red blood cell transfusion in the two weeks prior to their participation in the trial